Modifying Dendritic Cell Activation with Plasmonic Nano Vectors

Abstract Dendritic cells (DCs) can acquire, process, and present antigens to T-cells to induce an immune response. For this reason, targeting cancer antigens to DCs in order to cause an immune response against cancer is an emerging area of nanomedicine that has the potential to redefine the way cert...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kieng Bao Vang, Ingrid Safina, Emilie Darrigues, Dmitry Nedosekin, Zeid A. Nima, Waqar Majeed, Fumiya Watanabe, Ganesh Kannarpady, Rajshekhar A. Kore, Daniel Casciano, Vladimir P. Zharov, Robert J. Griffin, Ruud P. M. Dings, Alexandru S. Biris
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/60dc30a25ba445379363dad684c8c45d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60dc30a25ba445379363dad684c8c45d
record_format	dspace
spelling	oai:doaj.org-article:60dc30a25ba445379363dad684c8c45d2021-12-02T11:41:21ZModifying Dendritic Cell Activation with Plasmonic Nano Vectors10.1038/s41598-017-04459-12045-2322https://doaj.org/article/60dc30a25ba445379363dad684c8c45d2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04459-1https://doaj.org/toc/2045-2322Abstract Dendritic cells (DCs) can acquire, process, and present antigens to T-cells to induce an immune response. For this reason, targeting cancer antigens to DCs in order to cause an immune response against cancer is an emerging area of nanomedicine that has the potential to redefine the way certain cancers are treated. The use of plasmonically active silver-coated gold nanorods (henceforth referred to as plasmonic nano vectors (PNVs)) as potential carriers for DC tumor vaccines has not been presented before. Effective carriers must be able to be phagocytized by DCs, present low toxicity, and induce the maturation of DCs—an early indication of an immune response. When we treated DCs with the PNVs, we found that the cell viability of DCs was unaffected, up to 200 μg/ml. Additionally, the PNVs associated with the DCs as they were phagocytized and they were found to reside within intracellular compartments such as endosomes. More importantly, the PNVs were able to induce expression of surface markers indicative of DC activation and maturation, i.e. CD40, CD86, and MHC class II. These results provide the first evidence that PNVs are promising carriers for DC-based vaccines and warrant further investigating for clinical use.Kieng Bao VangIngrid SafinaEmilie DarriguesDmitry NedosekinZeid A. NimaWaqar MajeedFumiya WatanabeGanesh KannarpadyRajshekhar A. KoreDaniel CascianoVladimir P. ZharovRobert J. GriffinRuud P. M. DingsAlexandru S. BirisNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kieng Bao Vang Ingrid Safina Emilie Darrigues Dmitry Nedosekin Zeid A. Nima Waqar Majeed Fumiya Watanabe Ganesh Kannarpady Rajshekhar A. Kore Daniel Casciano Vladimir P. Zharov Robert J. Griffin Ruud P. M. Dings Alexandru S. Biris Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
description	Abstract Dendritic cells (DCs) can acquire, process, and present antigens to T-cells to induce an immune response. For this reason, targeting cancer antigens to DCs in order to cause an immune response against cancer is an emerging area of nanomedicine that has the potential to redefine the way certain cancers are treated. The use of plasmonically active silver-coated gold nanorods (henceforth referred to as plasmonic nano vectors (PNVs)) as potential carriers for DC tumor vaccines has not been presented before. Effective carriers must be able to be phagocytized by DCs, present low toxicity, and induce the maturation of DCs—an early indication of an immune response. When we treated DCs with the PNVs, we found that the cell viability of DCs was unaffected, up to 200 μg/ml. Additionally, the PNVs associated with the DCs as they were phagocytized and they were found to reside within intracellular compartments such as endosomes. More importantly, the PNVs were able to induce expression of surface markers indicative of DC activation and maturation, i.e. CD40, CD86, and MHC class II. These results provide the first evidence that PNVs are promising carriers for DC-based vaccines and warrant further investigating for clinical use.
format	article
author	Kieng Bao Vang Ingrid Safina Emilie Darrigues Dmitry Nedosekin Zeid A. Nima Waqar Majeed Fumiya Watanabe Ganesh Kannarpady Rajshekhar A. Kore Daniel Casciano Vladimir P. Zharov Robert J. Griffin Ruud P. M. Dings Alexandru S. Biris
author_facet	Kieng Bao Vang Ingrid Safina Emilie Darrigues Dmitry Nedosekin Zeid A. Nima Waqar Majeed Fumiya Watanabe Ganesh Kannarpady Rajshekhar A. Kore Daniel Casciano Vladimir P. Zharov Robert J. Griffin Ruud P. M. Dings Alexandru S. Biris
author_sort	Kieng Bao Vang
title	Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
title_short	Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
title_full	Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
title_fullStr	Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
title_full_unstemmed	Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
title_sort	modifying dendritic cell activation with plasmonic nano vectors
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/60dc30a25ba445379363dad684c8c45d
work_keys_str_mv	AT kiengbaovang modifyingdendriticcellactivationwithplasmonicnanovectors AT ingridsafina modifyingdendriticcellactivationwithplasmonicnanovectors AT emiliedarrigues modifyingdendriticcellactivationwithplasmonicnanovectors AT dmitrynedosekin modifyingdendriticcellactivationwithplasmonicnanovectors AT zeidanima modifyingdendriticcellactivationwithplasmonicnanovectors AT waqarmajeed modifyingdendriticcellactivationwithplasmonicnanovectors AT fumiyawatanabe modifyingdendriticcellactivationwithplasmonicnanovectors AT ganeshkannarpady modifyingdendriticcellactivationwithplasmonicnanovectors AT rajshekharakore modifyingdendriticcellactivationwithplasmonicnanovectors AT danielcasciano modifyingdendriticcellactivationwithplasmonicnanovectors AT vladimirpzharov modifyingdendriticcellactivationwithplasmonicnanovectors AT robertjgriffin modifyingdendriticcellactivationwithplasmonicnanovectors AT ruudpmdings modifyingdendriticcellactivationwithplasmonicnanovectors AT alexandrusbiris modifyingdendriticcellactivationwithplasmonicnanovectors
_version_	1718395400223719424

Modifying Dendritic Cell Activation with Plasmonic Nano Vectors

Ejemplares similares